With the increasing occurrence of severe PV,standard biomedical treatments such as IL-17A inhibitors, TNF-ɑ inhibitors and IL-12/23 inhibitors have been extensively utilized for PV (Dapavo et al., 2022; Bai et al., 2019; Mahil and Smith, 2019). This evidence concerns the gene IL17A and acquired polycythemia vera.